Gajdács Márió, Urbán Edit, Stájer Anette, Baráth Zoltán
Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös utca 6., 6720 Szeged, Hungary.
Institute of Medical Microbiology, Faculty of Medicine, Semmelweis University, Nagyvárad tér 4., 1089 Budapest, Hungary.
Eur J Investig Health Psychol Educ. 2021 Jan 19;11(1):71-82. doi: 10.3390/ejihpe11010006.
The reduction in infectious disease morbidity and mortality may be attributed to a variety of factors; however, improved sanitation and public health, and the introduction of vaccines and antibiotics are among the most significant. The development of antimicrobial resistance (AMR) in bacterial pathogens is an expected consequence of evolutionary adaptation to these noxious agents and the widespread use of these drugs has significantly sped up this process. Infections caused by multidrug resistant pathogens are directly associated with worse clinical outcomes, longer hospital stays, excess mortality in the affected patients and an increasing burden and costs on the healthcare infrastructure. The Sustainable Development Goals (SDGs) were published in 2015 by the United Nations to serve as a global blueprint for a better, more equitable, more sustainable life on our planet. The SDGs contextualize AMR as a global public health and societal issue; in addition, the continuing emergence of AMR may limit the attainment on many SDGs. The aim of this mini-review is to provide insight on the interface between attainment of SDGs and the clinical problem of drug resistance in bacteria.
传染病发病率和死亡率的降低可能归因于多种因素；然而，卫生条件和公共卫生的改善，以及疫苗和抗生素的引入是其中最重要的因素。细菌病原体中抗菌药物耐药性（AMR）的发展是对这些有害物质进行进化适应的一个预期结果，而这些药物的广泛使用显著加速了这一过程。由多重耐药病原体引起的感染与更差的临床结果、更长的住院时间、受影响患者的额外死亡率以及医疗基础设施日益增加的负担和成本直接相关。联合国于2015年发布了可持续发展目标（SDGs），作为在我们星球上实现更美好、更公平、更可持续生活的全球蓝图。可持续发展目标将抗菌药物耐药性视为一个全球公共卫生和社会问题；此外，抗菌药物耐药性的持续出现可能会限制许多可持续发展目标的实现。本综述的目的是深入探讨可持续发展目标的实现与细菌耐药性这一临床问题之间的联系。
